Studies how doctors choose first treatment for advanced bladder cancer
Observes why doctors pick platinum chemotherapy for adults with metastatic urothelial carcinoma.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 20 Apr 2025
- Planned end
- 20 Apr 2026
- Type of study
- Observational
- Record updated
- 14 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic urothelial carcinoma who have received first-line treatment for the spread disease since October 2024.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Metastatic urothelial carcinoma
- Earlier treatment
- Must have been treated with first-line metastatic therapy since October 2024.
Main reasons for not taking part
- Patients who said they do not want to take part in the study
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients over 18 years of age
- Metastatic urothelial carcinoma
- Treated with first-line metastatic therapy since October 2024
Who cannot take part
- Patient who expressed opposition to participating in the study
Where in France
- Service Oncologie Médicale - CHU de Strasbourg - FranceStrasbourg, FranceContact: Philippe Barthélémy, MDTaking people
About the trial
What the trial wants to find out
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
- Plain-language title
- Studies how doctors choose first treatment for advanced bladder cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 14 January 2026